Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#81 / 81 Total
NNVC - NanoViricides Inc - Stock Price Chart
TickerNNVC [AMEX]
CompanyNanoViricides Inc
CountryUSA
IndustryBiotechnology
Market Cap13.43MEPS (ttm)-0.80
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.25%
P/S-EPS next 5Y-
P/B1.08EPS Q/Q-19.83%
Dividend-Sales Q/Q-
Insider Own4.62%Inst Own10.28%
Insider Trans0.00%Inst Trans19.17%
Short Float1.00%EarningsFeb 16/a
Analyst Recom1.00Target Price6.50
Avg Volume29.36K52W Range1.00 - 2.00
Apr-30-24 06:30AM NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon (ACCESSWIRE) +6.19%
Feb-15-24 06:30AM NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon (ACCESSWIRE)
Feb-14-24 05:11PM NanoViricides: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Feb-01-24 06:20AM Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics (ACCESSWIRE)
Jan-29-24 06:30AM Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found (ACCESSWIRE) +9.35%
Jan-04-24 06:30AM NanoViricides to Present at the Biotech Showcase in San Fransisco (ACCESSWIRE) +5.83%
Nov-29-23 01:32PM NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387 (News Direct)
Nov-28-23 06:40AM The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Companys Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides (ACCESSWIRE) +13.73%
Nov-15-23 06:45AM NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications (ACCESSWIRE) -9.70%
05:04AM NanoViricides: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. It focuses on anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs. The company was founded by Anil R. Diwan on April 1, 2005 and is headquartered in Shelton, CT.
123456789
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.